AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7378234 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol 0.4 mg kg‐1 and atropine 1.5 mg i.v. shortly before anaesthesia; practolol 0.2 mg kg‐1 during anaesthesia
Number of subjects: 25
Study 7378234 — intervention group
Group type: COMPARATOR
Intervention: Atropine 0.5 mg before anaesthesia
Number of subjects: 25
Study 31705591 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention programme (n = 102)
Number of subjects: 202
Study 31705591 — intervention group
Group type: COMPARATOR
Intervention: Attention from intervener (n = 100)
Number of subjects: 202
Study 31679508 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Animated Activity Questionnaire (AAQ)
Number of subjects: 200
Study 31679508 — intervention group
Group type: COMPARATOR
Intervention: HOOS/KOOS paper questionnaire
Number of subjects: 200
Study 31679508 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between AAQ and HOOS/KOOS
Number of subjects: 200
Study 27671861 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative embolization (POE) with polyvinyl alcohol (PVA) particles
Number of subjects: 64
Study 27671861 — intervention group
Group type: COMPARATOR
Intervention: Surgery without POE
Number of subjects: 64
Study 26403361 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ankle dorsiflexion stretching for 15 min per leg, four days per week for six weeks.
Number of subjects: 13
Study 26403361 — intervention group
Group type: COMPARATOR
Intervention: Normal routine (control group).
Number of subjects: 13
Study 23673793 — intervention group
Group type: EXPERIMENTAL
Intervention: Keep It Up! intervention
Number of subjects: 102
Study 23673793 — intervention group
Group type: COMPARATOR
Intervention: Online didactic HIV knowledge condition
Number of subjects: 102
Study 21345132 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving skills training based on metacognitive principles
Number of subjects: 32
Study 21345132 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 32
Study 19330391 — intervention group
Group type: COMPARATOR
Intervention: Titanium-coated cups
Number of subjects: 26
Study 19330391 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated cups
Number of subjects: 26
Study 19330391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 17353513 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg) + HCTZ (25 mg)
Number of subjects: 489
Study 17353513 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg) + HCTZ (25 mg)
Number of subjects: 489
Study 17353513 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg) + HCTZ (25 mg)
Number of subjects: 489
Study 17353513 — intervention group
Group type: COMPARATOR
Intervention: Placebo + HCTZ (25 mg)
Number of subjects: 489
Study 14729863 — intervention group
Group type: EXPERIMENTAL
Intervention: -1131C allele carriers (n = 54)
Number of subjects: 608
Study 14729863 — intervention group
Group type: EXPERIMENTAL
Intervention: 19W carriers (n = 44)
Number of subjects: 608
Study 14729863 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil treatment
Number of subjects: 608
Study 11502525 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinafloxacin (CI‐960) administered intravenously and orally, dosage not specified, single and twice-daily doses.
Number of subjects: 0
Study 9474074 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy
Number of subjects: 161
Study 9474074 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSQOLI
Number of subjects: 161
Study 9474074 — intervention group
Group type: EXPERIMENTAL
Intervention: QLQ‐C30
Number of subjects: 161
Study 9474074 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSQOLI linear analog scale
Number of subjects: 161
Study 9474074 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSQOLI and QLQ‐C30
Number of subjects: 161
Study 8582390 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (acebutalol or atenolol)
Number of subjects: 19
Study 8582390 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 19
Study 2198911 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (n = 9)
Number of subjects: 18
Study 2198911 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (n = 9)
Number of subjects: 18
Study 2198911 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 18
Study 2198911 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol and Atenolol
Number of subjects: 18
Study 219509 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol-hydrochlorothiazide-amiloride combination
Number of subjects: 283
Study 219509 — intervention group
Group type: COMPARATOR
Intervention: beta-blocker (timolol) alone
Number of subjects: 283
Study 219509 — intervention group
Group type: COMPARATOR
Intervention: combination of two diuretics (hydrochlorothiazide + amiloride)
Number of subjects: 283
Study 219509 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker/diuretic combination
Number of subjects: 283
Study 29901581 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapatellar approach
Number of subjects: 0
Study 29901581 — intervention group
Group type: COMPARATOR
Intervention: Infrapatellar approach
Number of subjects: 0
Study 26541570 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 4736
Study 26541570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study 24568963 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 6500
Study 24568963 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose clonidine
Number of subjects: 6500
Study 24568963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6500
Study 24568963 — intervention group
Group type: EXPERIMENTAL
Intervention: Single measurement of serum creatinine between 3 and 12 months after surgery
Number of subjects: 6500
Study 22950716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified physical activity counseling (5 sessions integrated into routine maternity visits, monthly group meetings)
Number of subjects: 399
Study 22950716 — intervention group
Group type: COMPARATOR
Intervention: Usual care (conventional practices continued)
Number of subjects: 399
Study 20230447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 252
Study 20230447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 18849226 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular outflow tract (RVOT) pacing
Number of subjects: 32
Study 18849226 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apex (RVA) pacing
Number of subjects: 32
Study 15888205 — intervention group
Group type: EXPERIMENTAL
Intervention: AR immunostaining in prostate cancer epithelial nuclei
Number of subjects: 40
Study 15888205 — intervention group
Group type: COMPARATOR
Intervention: AR immunostaining in benign prostate
Number of subjects: 40
Study 15888205 — intervention group
Group type: COMPARATOR
Intervention: Percentage of immunopositive nuclei and percentage of immunopositive nuclear area
Number of subjects: 40
Study 12960909 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (30 mg subcutaneously every 12 hr)
Number of subjects: 95
Study 12960909 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 IU subcutaneously once daily)
Number of subjects: 95
Study 10672813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepitel silicone net dressings
Number of subjects: 45
Study 10672813 — intervention group
Group type: COMPARATOR
Intervention: Paraffin gauze dressings
Number of subjects: 45
Study 8554022 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 24
Study 8554022 — intervention group
Group type: COMPARATOR
Intervention: Tissue plasminogen activator (TPA)
Number of subjects: 24
Study 8554022 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase and TPA
Number of subjects: 24
Study 2061445 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 10% cyclosporine in oily solution
Number of subjects: 26
Study 2061445 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 26
Study 2061445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thymopentin
Number of subjects: 26
Study 6352005 — intervention group
Group type: EXPERIMENTAL
Intervention: prednimustine continuously; 40 mg/m2 d
Number of subjects: 201
Study 6352005 — intervention group
Group type: EXPERIMENTAL
Intervention: prednimustine intermittently; 160 mg/m2 d 1 to 5, repeated every three weeks
Number of subjects: 201
Study 6352005 — intervention group
Group type: COMPARATOR
Intervention: chlorambucil 8 mg/m2 d plus prednisolone 8 mg/m2 d, both given continuously
Number of subjects: 201
Study 4085127 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal kinesthetic imagery training
Number of subjects: 59
Study 4085127 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal visual imagery training
Number of subjects: 59
Study 4085127 — intervention group
Group type: EXPERIMENTAL
Intervention: External visual imagery training
Number of subjects: 59
Study 4085127 — intervention group
Group type: COMPARATOR
Intervention: Control training group
Number of subjects: 59
Study 30851006 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed titration of Gla-300
Number of subjects: 0
Study 30851006 — intervention group
Group type: COMPARATOR
Intervention: Physician-managed titration of Gla-300
Number of subjects: 0
Study 29417371 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated health checks (maximum of three checks between 1982 and 1994)
Number of subjects: 17845
Study 29417371 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health checks)
Number of subjects: 17845
Study 26601770 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic regulation therapy (ART) with chronic vagus nerve stimulation
Number of subjects: 25
Study 24644249 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 130
Study 24644249 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 130
Study 24644249 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 130
Study 22576327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical 40 mg HA, 10 ml of 2 % lidocaine and 5 ml of 8.4 % sodium bicarbonate
Number of subjects: 48
Study 22576327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical 40 mg HA
Number of subjects: 48
Study 22576327 — intervention group
Group type: COMPARATOR
Intervention: Intravesical 10 ml of 2 % lidocaine and 5 ml of 8.4 % sodium bicarbonate
Number of subjects: 48
Study 20067331 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 0
Study 20067331 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 17506903 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, weekly, hospital-based exercise
Number of subjects: 0
Study 17506903 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised home exercise
Number of subjects: 0
Study 15951939 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary stent
Number of subjects: 81
Study 15951939 — intervention group
Group type: COMPARATOR
Intervention: T-tube
Number of subjects: 81
Study 12950540 — intervention group
Group type: EXPERIMENTAL
Intervention: Post Mode Switching Overdrive Pacing (PMOP) active (120 beats/min for 2 min)
Number of subjects: 37
Study 12950540 — intervention group
Group type: COMPARATOR
Intervention: Post Mode Switching Overdrive Pacing (PMOP) inactive
Number of subjects: 37
Study 11187670 — intervention group
Group type: EXPERIMENTAL
Intervention: Gibbs sampling technique
Number of subjects: 0
Study 11187670 — intervention group
Group type: EXPERIMENTAL
Intervention: Techniques based on one long single chain and on multiple chains
Number of subjects: 0
Study 8876938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (Fenistil OAD)
Number of subjects: 18
Study 8876938 — intervention group
Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 18
Study 8876938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8876938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (Fenistil retard)
Number of subjects: 18
Study 1716558 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (3 doses)
Number of subjects: 0
Study 1716558 — intervention group
Group type: COMPARATOR
Intervention: Peripheral anticholinergic agent
Number of subjects: 0
Study 1716558 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy elderly)
Number of subjects: 0
Study 6296673 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpesvirus infections (primary or reactivated) in the first three months after transplantation
Number of subjects: 28
Study 6296673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus infections in less heavily immunosuppressed recipients of organs from living related donors
Number of subjects: 28
Study 6296673 — intervention group
Group type: EXPERIMENTAL
Intervention: Low OKT4/OKT8 ratios (< 1.0)
Number of subjects: 28
Study 6296673 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal dysfunction with low OKT4/OKT8 ratio
Number of subjects: 28
Study 6296673 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of T-lymphocyte subsets
Number of subjects: 28
Study 31913424 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumateperone 42 mg
Number of subjects: 450
Study 31913424 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumateperone 28 mg
Number of subjects: 450
Study 31913424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 30799959 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly dual injections
Number of subjects: 88
Study 30799959 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tablets
Number of subjects: 88
Study 30799959 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly vaginal rings
Number of subjects: 88
Study 28647746 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided IRT
Number of subjects: 127
Study 28647746 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided IRT
Number of subjects: 127
Study 28647746 — intervention group
Group type: COMPARATOR
Intervention: Nightmare frequency control group
Number of subjects: 127
Study 28647746 — intervention group
Group type: COMPARATOR
Intervention: Narrative control group
Number of subjects: 127
Study 27048954 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 52
Study 27048954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 24876619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hepatic-directed vesicle-insulin (HDV-I) 0.05 U/kg
Number of subjects: 6
Study 24876619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hepatic-directed vesicle-insulin (HDV-I) 0.1 U/kg
Number of subjects: 6
Study 24876619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hepatic-directed vesicle-insulin (HDV-I) 0.2 U/kg
Number of subjects: 6
Study 24876619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hepatic-directed vesicle-insulin (HDV-I) 0.4 U/kg
Number of subjects: 6
Study 24876619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 22178160 — intervention group
Group type: EXPERIMENTAL
Intervention: microbubbles with three‐dimensional (3‐D) guided high mechanical index impulses (1.18) for 15 min
Number of subjects: 10
Study 22178160 — intervention group
Group type: COMPARATOR
Intervention: placebo without ultrasound
Number of subjects: 10
Study 19675330 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight lifting
Number of subjects: 141
Study 19675330 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study 17451119 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider
Number of subjects: 50
Study 17451119 — intervention group
Group type: COMPARATOR
Intervention: Standard instruments
Number of subjects: 50
Study 15111663 — intervention group
Group type: EXPERIMENTAL
Intervention: CEMRA
Number of subjects: 167
Study 15111663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DUS and CEMRA
Number of subjects: 167
Study 15111663 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective DUS review
Number of subjects: 167
Study 12183696 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude thrust manipulation to the talocrural joint
Number of subjects: 41
Study 12183696 — intervention group
Group type: COMPARATOR
Intervention: Control group (no manipulation)
Number of subjects: 41
Study 10547079 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan, 75 mg/day
Number of subjects: 20
Study 10547079 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal GTN, 0.6 mg/h
Number of subjects: 20
Study 10547079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8904738 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 304
Study 8904738 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital combined with promethazine
Number of subjects: 304
Study 1855357 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day enalapril
Number of subjects: 42
Study 1855357 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day enalapril
Number of subjects: 42
Study 1855357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6185553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn 2% (nonirritant dose)
Number of subjects: 10
Study 6185553 — intervention group
Group type: COMPARATOR
Intervention: Control (no cromolyn)
Number of subjects: 10
Study 31602822 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate in capsules (500 mg·kg‐1 body mass)
Number of subjects: 24
Study 31602822 — intervention group
Group type: COMPARATOR
Intervention: Sodium citrate in solution (500 mg·kg‐1 body mass)
Number of subjects: 24
Study 29301919 — intervention group
Group type: EXPERIMENTAL
Intervention: (bio)feedback-guided training
Number of subjects: 218
Study 29301919 — intervention group
Group type: COMPARATOR
Intervention: Enhanced education group
Number of subjects: 218
Study 29301919 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 218
Study 26748056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant
Number of subjects: 146
Study 26748056 — intervention group
Group type: COMPARATOR
Intervention: Implant removal surgeries
Number of subjects: 146
Study 24281290 — intervention group
Group type: EXPERIMENTAL
Intervention: IV racemic ketamine 0.5 mg/kg preincisional +0.25 mg/kg/h for 48 h
Number of subjects: 104
Study 24281290 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural racemic ketamine 0.5 mg/kg preincisional +0.25 mg/kg/h for 48 h
Number of subjects: 104
Study 24281290 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 104
Study 24281290 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Kiv, Kep, S)
Number of subjects: 104
Study 24160246 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised Oral Hygiene Advice (OHA)
Number of subjects: 1860
Study 24160246 — intervention group
Group type: COMPARATOR
Intervention: Routine Oral Hygiene Advice (OHA)
Number of subjects: 1860
Study 24160246 — intervention group
Group type: EXPERIMENTAL
Intervention: No Periodontal Instrumentation (PI)
Number of subjects: 1860
Study 24160246 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 monthly Periodontal Instrumentation (PI)
Number of subjects: 1860
Study 24160246 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 monthly Periodontal Instrumentation (PI)
Number of subjects: 1860
Study 20648579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node dissection (SLND)
Number of subjects: 3983
Study 20648579 — intervention group
Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 3983
Study 18468012 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (Group S)
Number of subjects: 16
Study 18468012 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 16
Study 16352880 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing xylitol + calcium lactate
Number of subjects: 10
Study 16352880 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing only xylitol
Number of subjects: 10
Study 16352880 — intervention group
Group type: COMPARATOR
Intervention: No gum chewing (control)
Number of subjects: 10
Study 12496308 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-oriented care training program
Number of subjects: 300
Study 12496308 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study 10823260 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide 800 mg/day
Number of subjects: 310
Study 10823260 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide 1200 mg/day
Number of subjects: 310
Study 10823260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 8938895 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Caloric Diet (VLCD)
Number of subjects: 20
Study 8938895 — intervention group
Group type: COMPARATOR
Intervention: Very Low-Caloric Diet (VLCD) after initial control period
Number of subjects: 20
Study 1389945 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan (100 mg)
Number of subjects: 9
Study 1389945 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 9
Study 1389945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3996172 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills intervention group (daily social-learning exercises)
Number of subjects: 21
Study 3996172 — intervention group
Group type: COMPARATOR
Intervention: Control group (learning medical facts about diabetes care)
Number of subjects: 21
Study 30421178 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg melatonin a day, administered 5 days a week for 28 days
Number of subjects: 60
Study 30421178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30421178 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg melatonin a day
Number of subjects: 60
Study 29876978 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-report survey
Number of subjects: 58